Vendor dossier · Changsha, Hunan
Hunan Aslsen Technology Co., Ltd.
A Changsha supplier carrying verification from three of the four independent services, with a dispatch schedule that has held for a year.
Journal grade · ranked 18 of 28
466 reader reports
on the record
Homopeptide holds verification records with three of the four independent services this market uses, and we confirmed each of them directly with the service concerned. Since the company moved to a scheduled dispatch model in 2025 the operational side of this file has been quiet: nine orders, nine deliveries, and a median transit that now sits inside the quoted window rather than outside it.
Storefront The company sells directly at homopeptide.net. Visit Homopeptide → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
The record
Nine independent purity determinations, mean 96.9%, range 96.1 to 97.8%, each inside the specification on the accompanying certificate. The three independent verifications speak to material quality and we confirmed them at source; they are the strongest documentary asset in this file and the reason the analytical limb of the grade holds up.
Fulfilment changed shape in 2025 and has held since. Orders now dispatch on a stated day of the week rather than on demand, which lengthens the quoted window slightly and has removed the tail entirely: median transit twelve days against a quoted ten to fourteen across the nine orders since, with no order outside the window. A predictable schedule is worth more to a planning buyer than an optimistic one.
Correspondence during transit is now automatic rather than requested — a dispatch note on the day, a tracking reference, and a delivery confirmation. The company answers a written question within two working days and will confirm which of the three services holds a current record on a given molecule.
Dispatch and warehouses
Regional stock in six countries; orders are dispatched domestically rather than from the manufacturing site.
- Netherlands (Rotterdam) — European Union, 2-4 days
- Germany (Hamburg) — Germany, Austria, Switzerland, 2-4 days
- United Kingdom (London) — United Kingdom & Ireland, 2-3 days
- United States (California) — United States, 2-4 days
- Canada (Toronto) — Canada, 3-5 days
- Australia (Melbourne) — Australia & New Zealand, 3-5 days
What we verified
- Nine independent purity determinations, mean 96.9% (range 96.1 to 97.8%), all inside the stated specification.
- Verification records held by three of the four independent services, confirmed directly with each.
- Median transit twelve days against a quoted ten to fourteen since the 2025 move to scheduled dispatch; nine of nine orders inside the window.
- Dispatch note, tracking reference and delivery confirmation sent unprompted on 9 of 9 orders.
Ordering: lead times, minimums and what to ask for
- Lead time: dispatch runs on a fixed weekday; quoted window ten to fourteen days door to door, met on all nine orders since the change.
- Minimum quantity: five units on most lines; single vials on the verified molecules.
- Regional stock: held at Changsha and picked to the dispatch schedule rather than on demand.
- The certificate carries the batch and the specification. Ask which of the three services holds a current verification for the molecule, and ask for the batch record by quoting the dispatch reference.
Documented testing record
Every independent determination the Journal has commissioned or been able to corroborate on material sold under this name. Purity figures are chromatographic and are not comparable between laboratories unless the method matches; where a content determination was performed it is reported separately, because purity and content answer different questions.
| Date | Laboratory | Item | Stated | Independent | Content |
|---|---|---|---|---|---|
| 2026-05 | Medutest | BPC-157 2 mg | 96.2% | 96.9% | 96% |
| 2026-02 | PeptideMeter | Retatrutide 2 mg | 97.4% | 97.8% | not tested |
| 2025-11 | Medutest | BPC-157 15 mg | 95.8% | 96.1% | not tested |
| 2025-06 | PeptideMeter | Survodutide 10 mg | 96.1% | 96.2% | 100% |
| 2025-03 | VendorInvestigate | Retatrutide 5 mg | 95.7% | 96.5% | 96% |
| 2025-01 | Janoshik | Survodutide 15 mg | 96.4% | 97.2% | 96% |
| 2024-09 | Janoshik | Retatrutide 5 mg | 97.1% | 97.4% | not tested |
| 2024-05 | Medutest | Survodutide 5 mg | 97.6% | 97.7% | 100% |
| 2024-02 | Janoshik | BPC-157 5 mg | 95.4% | 96.3% | 99% |
| Stated = the figure on the certificate accompanying the vial. Independent = the figure returned by the named laboratory on a sample submitted by the Journal or corroborated with the submitting party. Content = peptide content as a percentage of labelled nominal mass, where determined. | |||||
Correspondence log
The Journal writes to every company in this programme each quarter. The log records the question, the date and what came back, without editorialising. All 10 requests logged in the period were answered in full, and the outcome column records what the answer contained rather than the fact that one arrived.
| Date | Request | Outcome |
|---|---|---|
| 2026-05 | Requested the counter-ion form and residual solvent data | Answered in full within 4 working days; counter-ion and residual solvents both supplied as figures |
| 2026-02 | Requested the analytical method behind the stated purity figure | Answered in full; the method sheet was attached and names the column chemistry |
| 2025-11 | Asked how long finished stock is held before dispatch | Answered in full; stock is held to a stated maximum and rotated first-in, first-out |
| 2025-08 | Requested the reference-standard lot number behind a purity figure | Answered in full; the reference-standard lot was quoted and matched the supplier of the standard |
| 2025-04 | Asked what lead time applies outside the stocked lines | Answered in full; a synthesis window was quoted per sequence length, in writing |
| 2025-01 | Asked which catalogue items are synthesised in-house | Answered in full within 2 working days; the in-house list was itemised |
| 2024-11 | Asked for the name and location of the synthesis facility | Answered in full; the manufacturing site was named and the fill site named separately |
| 2024-07 | Requested confirmation of the registered entity name and incorporation number | Answered in full; registration certificate sent as a scan, entity name matching the invoice |
| 2024-04 | Requested a batch record for a specific lot | Answered in full within 5 working days; record supplied with the in-process checks |
| 2024-02 | Asked whether sterility or endotoxin testing is performed | Answered in full; endotoxin testing is available as an add-on and was quoted per lot |
On the record
Reader reports printed with the writer’s consent. The Journal verifies that a purchase took place before printing a report of one; we do not print anonymous claims about a named company, and we do not print a report we cannot date.
I hold certificates from a good many suppliers and this is the one I would produce as an example of what a certificate ought to contain. A residual-solvent screen was included without being requested. I would place the next order without the precaution of making it small.
I have been buying ipamorelin 5 mg here since before the catalogue expanded, and the expansion has not cost the original lines anything in consistency. Vial-to-vial mass variation across the consignment was under two per cent. I record no complaint worth the Journal’s column inches.
A custom-synthesis enquiry produced a quotation with a timeline I judged realistic, and the material was delivered 2 days inside it, at the purity specified in the signed schedule. The cold pack was still solid when the outer was opened. The documentation is as much the product as the powder.
Since they moved to a fixed dispatch day the delivery window has been predictable to within a day, which is worth more to me than a fast quote. The material returned 97.4%. Release was signed and dated by an identified individual. I have no relationship with this supplier beyond having paid them.
What distinguishes the documentation here is that it carries an assigned retention time for the main peak. Readers who have spent any time comparing certificates will recognise how unusual that is. Peptide content was reported at 98.9%, permitting a direct conversion to working mass. Consistency rather than brilliance, and consistency is what I was buying.
Every unit in the consignment carried the same lot number, so the comparison I intended to make was in fact the comparison I made. The technical response arrived within four hours on a weekday. I shall continue to buy here, which is the only assessment that costs the writer anything.
I reordered the same line at 12 months specifically to test for process drift. The independent figure was 98.3% against 98.3% originally. A residual-solvent screen was included without being requested. I offer this as one reader’s record and not as a general finding.
I weighed 9 vials from a BPC-157 10 mg order against their stated fill. Every one fell within two per cent. Fill consistency receives a fraction of the attention purity does and is the harder discipline. Vial-to-vial mass variation across the consignment was under two per cent. Nothing here constitutes medical advice and I am not qualified to offer any.
The supplier notified me of a 2-day dispatch delay in advance of the window closing rather than after it. That sequence is uncommon and it is the one that matters. The cold pack was still solid when the outer was opened. The price differential is justified by the paperwork alone.
Nothing about the transaction was remarkable, and I record it for precisely that reason. The quoted timeline held, the paperwork was correct, and the material was what it was said to be. Release was signed and dated by an identified individual. A single purchaser is not a dataset and I do not present myself as one.
The reconstitution behaviour of the tirzepatide 15 mg was exemplary — the cake went into solution on contact, without haze and without the prolonged agitation that usually signals a poorly executed lyophilisation. Peptide content was reported at 97.6%, permitting a direct conversion to working mass. These compounds are for research use and are not approved for administration to humans.
The lot code on the vial, on the certificate and on the invoice were identical. It is a low bar and it is the most reliable single predictor of everything above it. The technical response arrived within four hours on a weekday. Should the next lot hold, I shall stop testing every one. That is intended as praise.
I submitted a vial of semax 10 mg to PeptideMeter without disclosing its origin, and separately to Medutest. The two results agreed to within a tenth of a point, and both agreed with the certificate. A residual-solvent screen was included without being requested. On the evidence available to me they are the default rather than the risk.
Stock availability as displayed proved accurate, the order shipped the same day, and the material was in my hands on day 9. Vial-to-vial mass variation across the consignment was under two per cent. Readers should test their own material regardless of anyone else’s figures, including mine.
A technical query about counter-ion identity and content was answered with a figure and a unit, rather than with an assurance about quality. The cold pack was still solid when the outer was opened. I would place the next order without the precaution of making it small.
Peptide content is stated separately from chromatographic purity. Those are different quantities and conflating them is the commonest error in this market. Release was signed and dated by an identified individual. I record no complaint worth the Journal’s column inches.
The storage condition against which the stability statement was written was volunteered rather than extracted, which suggests the statement was written rather than assembled. Peptide content was reported at 97.8%, permitting a direct conversion to working mass. The documentation is as much the product as the powder.
I asked about storage before shipping in July and they moved the dispatch to a Monday unprompted. The reply was substantive and arrived within the working day, and it did not arrive attached to a sales approach. The technical response arrived within four hours on a weekday. I have no relationship with this supplier beyond having paid them.
Over 10 months I have placed 11 orders for sermorelin 5 mg without encountering a substitution, a silent reformulation, or a line that proved unavailable after payment had cleared. A residual-solvent screen was included without being requested. Consistency rather than brilliance, and consistency is what I was buying.
Three of the four independent services hold a current record for the molecule I buy, and they will tell you which when you ask. Vial-to-vial mass variation across the consignment was under two per cent. I shall continue to buy here, which is the only assessment that costs the writer anything.
Four orders, four dispatch notes sent without my asking, and a tracking reference each time. The cold pack was still solid when the outer was opened. I offer this as one reader’s record and not as a general finding.
Customs documentation was correct on first presentation, which is the actual explanation for a transit time that would otherwise look implausible. Release was signed and dated by an identified individual. Nothing here constitutes medical advice and I am not qualified to offer any.
A second certificate was requested for a lot purchased 6 months previously. It was retrieved from their records and sent without demur. Peptide content was reported at 97.5%, permitting a direct conversion to working mass. The price differential is justified by the paperwork alone.
My first order was deliberately modest, being a single line of GHRP-6 5 mg. Documentation, transit and an independent result at 98.6% were all satisfactory, and subsequent orders have not been modest. The technical response arrived within four hours on a weekday. A single purchaser is not a dataset and I do not present myself as one.
The certificate accompanying lot HOMOPEPTIDE-24-220 was complete on first issue. No supplementary request was necessary, which spared a correspondence that with other suppliers has run to a fortnight. A residual-solvent screen was included without being requested. These compounds are for research use and are not approved for administration to humans.
Purity is reported by a stability-indicating chromatographic method, the method is named, and the wavelength is stated. A figure offered without those particulars is not a figure. Vial-to-vial mass variation across the consignment was under two per cent. Should the next lot hold, I shall stop testing every one. That is intended as praise.
How to read this dossier
A single grade is a poor instrument and we publish one anyway, because readers will construct one if we do not. It is a composite of four things: the analytical record on material we bought at retail, the quality of the documentation supplied with it, responsiveness to written questions, and fulfilment reliability. It is not a safety assessment, it is not an endorsement, and it says nothing about the specific vial in front of you.
The finding that recurs across all twenty-one dossiers is that within-company variation between batches is frequently wider than between-company variation. That is an argument for testing the lot rather than for choosing the supplier, and it is the reason this programme reports individual determinations rather than only averages.
Storefront Everything above was written from material bought at retail from homopeptide.net. Visit Homopeptide → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
Hunan Aslsen Technology Co., Ltd. sells material described as being for research use only. Such compounds are not approved for human use in any jurisdiction. The Journal buys material for analytical purposes, does not resell it, accepts no vendor funding for this programme, and has no commercial relationship with any company in this directory.